Iressa

Cat. No. 3000

Iressa C22H24ClFN4O3 [184475-35-2]

Price and Availability

For Iressa pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Special Conditions

No more than 1 g per individual per year to be sold without prior permission from the license holder.

Alternative Names: Gefitinib, ZD 1839

Chemical Name: N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine

Biological Activity

Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts.

Licensing Information

Sold for research purposes only under agreement from AstraZeneca

Technical Data

M.Wt:
446.9
Formula:
C22H24ClFN4O3
Solubility:
Soluble to 100 mM in DMSO and to 10 mM in ethanol
Purity:
>98 %
Storage:
Store at RT
CAS No:
184475-35-2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

McKillop et al (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 4 641. PMID: 15827338.

Baselga et al (2000) ZD1839 ('Iressa'), as an anticancer agent. Drugs 60 (Suppl. 1) 33. PMID: 11129170.

Ciardiello et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 6 2053. PMID: 10815932.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products. Selected citations for Iressa include:

Curran et al (2015) Architecture of Chimeric Spheroids Controls Drug Transport. Cancer Microenviron 8 101. PMID: 26239082.

Lindholm et al (2015) Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity. J Clin Cell Immunol 6. PMID: 26317041.

Qawasmi et al (2014) Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Front Pharmacol 5 257. PMID: 25484865.

Kitazono et al (2013) Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol 43 1846. PMID: 24100792.

McMellen et al (2010) Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery 148 364. PMID: 20471049.

Do you know of a great paper that uses Iressa from Tocris? If so please let us know.show all ▼show less ▲

View Related Products by Product Action

Keywords: Iressa, supplier, Orally, active, selective, EGFR, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, ErbB, Her, Receptor, Tyrosine, Kinases, RTKs, AstraZeneca, ZD1839, Tocris Bioscience, EGFR Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Life Science Poster

Our Schizophrenia poster higlights the targets and pathways representing the most promising strategies to pursue for novel drug development. Request copy today.

divider line

New Products in this Area

HIOC

Selective TrkB receptor agonist; neuroprotectant

AV 412

Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinases

CP 724714

Potent and selective ErbB2 inhibitor

Mitoglitazone

Insulin sensitizer; exhibits low binding affinity at PPARγ

PF 6274484

High affinity and potent covalent EGFR kinase inhibitor

Canertinib dihydrochloride

Potent EGFR kinase inhibitor

CHMFL-FLT3-122

Potent and selective FLT3 inhibitor

GW 2580

Selective cFMS kinase inhibitor; orally bioavailable

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Miptech

MipTech

September 20 - 22, 2016

Basel, Switzerland

Booth: A46